FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Waggoner Kenneth L. 2. Date of Event Requiring Statement (MM/DD/YYYY)
8/10/2021 

 3. Issuer Name and Ticker or Trading Symbol PharmaCyte Biotech, Inc. [PMCB]
(Last)       (First)       (Middle)
23046 AVENIDA DE LA CARLOTA, SUITE 600		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chairman, CEO, Pres and GC /
(Street)
LAGUNA HILLS, CA 92653      
(City)             (State)             (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  20600 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  3/9/2017  3/9/2022  Common Stock  3000 (1) $156.00 (2) D   
Stock Option (right to buy)  1/1/2018  1/1/2023  Common Stock  3000 (1) $83.70 (2) D   
Stock Option (right to buy)  3/20/2019  3/20/2024  Common Stock  3000 (1) $74.25 (2) D   
Stock Option (right to buy)  1/2/2020  1/1/2025  Common Stock  3000 (1) $61.20 (2) D   
Stock Option (right to buy)  1/1/2021 (3) 12/31/2025  Common Stock  3000 (1) $10.05 (2) D   

Explanation of Responses:
(1)  The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
(2)  The exercise price has been adjusted to reflect the Reverse Split.
(3)  The option vested in twelve equal monthly installments beginning on January 1, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Waggoner Kenneth L.
23046 AVENIDA DE LA CARLOTA
SUITE 600
LAGUNA HILLS, CA 92653		 X
Chairman, CEO, Pres and GC

Signatures
/s/ Kenneth L. Waggoner 8/31/2021
**Signature of Reporting Person Date
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more PharmaCyte Biotech Charts.
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more PharmaCyte Biotech Charts.